Hungary to issue bonds for Gedeon Richter; China Pharma offers $318M for Sihuan;

> Hungary plans to issue new convertible bonds worth around €800 million to refinance expiring debt held by pharmaceutical firm Gedeon Richter. Report

> Shares of Sihuan Pharmaceutical surged to a record after China Pharma, a private-equity unit of Morgan Stanley, offered to buy the Singapore-based drugmaker for some $318 million. Report

> French drugmaker Sanofi-Aventis and Belgium's UCB said their once-daily allergy medication Xyzal has received expanded FDA approval for children as young as six months. Report

> Medtronic's fiscal first quarter earnings dropped by 38 percent on restructuring and litigation charges. Report

> In news that could broaden use of human papillomavirus vaccines, Spanish researchers found that HPV is to blame for half of all cases of cancer of the penis. Report

> Cambrex, an active pharmaceutical ingredient provider, received an FDA warning letter on collection and maintenance of lab data at its manufacturing facility in Milan, Italy. Report

Biotech News

> Valeant Pharmaceuticals has won rare praise for designing a pay package for its CEO that rewards long-term success. Ironically, the company reported a key failure in a mid-stage trial the same day the Wall Street Journal echoed some high-profile kudos for the way the developer is compensating Chief Executive J. Michael Pearson. Report

> Complete Genomics has snared a $45 million round to finance development of new, and radically cheaper, sequencing services. Report

> P&G announced it will sell its entire prescription drug division in a $3.1 billion deal with specialty drugmaker Warner Chilcott. Report

> Shares of Switzerland's Santhera Pharmaceuticals got a boost this morning after the developer announced a $192 million licensing pact with Biovail for its experimental drug for dyskinesia in Parkinson's disease. Report

Research News

> Following a stem cell transplant with a cancer vaccine just weeks later appears to reduce complications for patients with a particularly hard-to-treat form of acute myeloid leukemia while significantly improving the immune system's ability to fight the disease. Report

> Working with embryonic stem cells, Australian scientists have created ‘glow-in-the-dark' blood cells that could help light the way to an artificial blood supply that would do away with the need for regular donations. Report

> Sigma-Aldrich is opening up a new lab that will create lines of genetically engineered rats for use in drug testing. A dozen scientists will work at the Sigma Advanced Genetic Engineering lab in St. Louis, where they will employ zinc finger nuclease technology to genetically modify the rats. Report

> Andrea Armani, an assistant professor at USC, has developed the world's first optical sensor that can spot an unlabelled molecule. And it works in a liquid. Report

And Finally... Johns Hopkins scientists say they have figured out how bacteria that cause diarrhea may also be the culprit in some colon cancers. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.